{"denoms":[{"counts":[{"groupId":"BG000","value":"32"}],"units":"Participants"}],"groups":[{"description":"Romidepsin was given as an infusion on Days 1, 8 and 15 of each 28-day cycle. Bortezomib was administered twice a week for two consecutive weeks (Days 1, 4, 8 and 11) followed by a 17-day rest period.\n\nPatients were treated to a maximum response plus two additional cycles or a maximum of eight cycles.","id":"BG000","title":"Romidepsin + Bortezomib"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"8.11","value":"63.7"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"18"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"14"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Native Hawaiian or Other Pacific Islander"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"24"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Other"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"12"}]}],"title":"Status 0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"14"}]}],"title":"Status 1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"Status 2"}],"description":"Eastern Cooperative Oncology Group (ECOG) Performance Status is a scale that measures how cancer affects a patient. The scale ranges from 0 (fully active) to 5 (dead). 0=Fully active without restriction; 1= Restricted in physically strenuous activity; 2= Ambulatory, capable of all selfcare.","paramType":"NUMBER","title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","unitOfMeasure":"participants"}]}